BRAF mutation predicts sensitivity to MEK inhibitionDavid B. Solit, Neal Rosen, Levi A. Garraway et al.|Nature|2005Cited by 1.3k
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W. Joseph, Neal Rosen, Ensar Halilovic et al.|Proceedings of the National Academy of Sciences|2010Cited by 447
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK DependenceMoriah H. Nissan, David B. Solit, Christine A. Pratilas et al.|Cancer Research|2014Cited by 310
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Giles Robinson et al.|Neuro-Oncology|2022Cited by 136
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF InhibitorMargaret K. Callahan, Jedd D. Wolchok, Gregg Masters et al.|Cancer Immunology Research|2013Cited by 120